German governments signed preliminary agreements back in the summer with German biotech companies BioNTech, a vaccine developer with Pfizer, and CureVac to supply 30 million and 20 million doses of their potential vaccines, respectively. The deals are controversial because EU governments have agreed not to negotiate bilateral supply agreements with vaccine manufacturers. According to German officials, deliveries to Germany under both deals will begin only after the companies have fulfilled their obligations to the EU to deliver 300 million doses of the Pfizer-BioNTech vaccine and 405 million doses of CureVac.
German governments signed preliminary agreements back in the summer with German biotech companies BioNTech, a vaccine developer with Pfizer, and CureVac to supply 30 million and 20 million doses of their potential vaccines, respectively. The deals are controversial because EU governments have agreed not to negotiate bilateral supply agreements with vaccine manufacturers. According to German officials, deliveries to Germany under both deals will begin only after the companies have fulfilled their obligations to the EU to deliver 300 million doses of the Pfizer-BioNTech vaccine and 405 million doses of CureVac. 
reuters.com
English (US) 